NEOSTIGMINE METHYL SULPHATE

The United States Food and Drug Administration (FDA) approved neostigmine methyl sulphate on 29 September 1972.

Neostigmine methyl sulfate is used in the management of myasthenia gravis. Additionally, Myostigmin is employed to reverse the effects of certain muscle relaxants post-surgery, treat postoperative paralytic ileus to enhance gastrointestinal motility, manage orthostatic hypotension by improving blood pressure regulation, and alleviate symptoms associated with dysautonomia. It is also utilized to counteract the neuromuscular effects of certain medications or toxins and explored for investigational uses beyond its standard indications.

A healthcare provider can administer Neostigmine methyl sulphate (Pyridostigmine) as an intravenous injection. The healthcare provider determines the exact dose, duration, and frequency.

Common side effects of Neostigmine methyl sulphate include nausea, vomiting, diarrhea, heightened salivation, sweating, muscle cramps, and blurred vision. On a more serious note, it can cause severe allergic reactions, slow heart rate, heart rhythm irregularities, pronounced muscle weakness, breathing difficulties, and signs of cholinergic crisis in cases of overdose, including excessive sweating, vomiting, diarrhea, and difficulty breathing.

Neostigmine methyl sulphate can lead to a cholinergic crisis and excessive acetylcholine activity. This can result in severe symptoms like excessive sweating, vomiting, muscle weakness, and difficulty breathing. It can affect heart rate and rhythm, potentially leading to bradycardia (slow heart rate) or heart block. It can worsen respiratory symptoms in conditions like asthma or other lung disorders. Its effects on increased stomach acid secretion can worsen gastrointestinal conditions, such as ulcers. Myostigmin can potentially trigger seizures, particularly in individuals with epilepsy or a history of seizures.

Monitor for signs of cholinergic crisis and immediately seek medical attention if symptoms like excessive sweating, vomiting, or difficulty breathing arise. Exercise caution in individuals with heart conditions. Regular cardiovascular monitoring is advisable to detect any heart rate or rhythm abnormalities. Use Myostigmin 0.5mg with caution in those with respiratory conditions. Monitor for any worsening of symptoms and discuss concerns with a healthcare provider. Discuss gastrointestinal health with your healthcare provider if you have conditions like ulcers. Monitor for any signs of seizure activity and inform your healthcare provider.

Inform your healthcare provider about allergies, medical history (including cardiac, pulmonary, gastrointestinal, and neurological conditions), and any medications before using neostigmine methyl sulphate. Dosage adjustments may be required for patients with liver or kidney impairment. Regular monitoring for adverse effects, signs of overdose (cholinergic crisis), and treatment response is essential. If you have respiratory conditions, cardiovascular disease, or neurological disorders, discuss how these may affect its use. Avoid abrupt discontinuation, self-administration without medical guidance, and sudden modifications to your treatment regimen. Store this medication appropriately, and contact your healthcare provider regarding any concerns or necessary adjustments to your treatment plan.

Goodman & Gilman's, The Pharmacological Basis of Therapeutics, Anticholinesterase agents, 12th edition, 2011, 250. KD Tripathi, Essentials of Medical Pharmacology, Cholinergic system and drugs, 7th edition, 2013, 105-111. Hameln Pharma Ltd, Electronic medicines compendium (EMC), [Revised on Dec 2020] [Accessed on August 30, 2023], https://www.medicines.org.uk/emc/files/pil.6268.pdf Fresenius Kabi USA LLC, US Food and Drug Administration, [Revised on Jan 2015] [Accessed on August 30, 2023], https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/203629s000lbl.pd